StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene r&d expenses

Research and development expenses are spending on new products and technology.

Neurogene's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.50M, up 28.7% year over year. For fiscal 2025 it was $75.01M, up 23.1% from the year before. Over ten years it grew 16.9% a year on average. The highest annual figure on record is $75.01M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$75.01M+23.1%
FY2024Dec 31, 2024$60.92M+37.2%
FY2023Dec 31, 2023$44.39M-6.5%
FY2022Dec 31, 2022$47.51M+21.3%
FY2021Dec 31, 2021$39.16M+60.9%
FY2020Dec 31, 2020$24.34M+451.1%
FY2019Dec 31, 2019$4.42M-89.4%
FY2018Dec 31, 2018$41.79M+15.2%
FY2017Dec 31, 2017$36.27M+27.8%
FY2016Dec 31, 2016$28.38M+79.6%
FY2015Dec 31, 2015$15.80M-12.6%
FY2014Dec 31, 2014$18.08M+137.9%
FY2013Dec 31, 2013$7.60M+25.7%
FY2012Dec 31, 2012$6.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$25.47M+31.5%
Q1 FY2026Mar 31, 2026$25.15M+41.6%
Q4 FY2025Dec 31, 2025$20.64M+34.5%
Q3 FY2025Sep 30, 2025$17.24M+5.9%
Q2 FY2025Jun 30, 2025$19.37M+23.0%
Q1 FY2025Mar 31, 2025$17.76M+31.2%
Q4 FY2024Dec 31, 2024$15.35M+26.0%
Q3 FY2024Sep 30, 2024$16.29M+40.3%
Q2 FY2024Jun 30, 2024$15.74M+52.5%
Q1 FY2024Mar 31, 2024$13.54M+31.7%
Q4 FY2023Dec 31, 2023$12.18M-25.6%
Q3 FY2023Sep 30, 2023$11.61M+22.5%
Q2 FY2023Jun 30, 2023$10.32M-5.8%
Q1 FY2023Mar 31, 2023$10.28M-3.9%
Q4 FY2022Dec 31, 2022$16.38M+67.8%
Q3 FY2022Sep 30, 2022$9.47M-4.3%
Q2 FY2022Jun 30, 2022$10.96M+11.5%
Q1 FY2022Mar 31, 2022$10.70M+10.2%
Q4 FY2021Dec 31, 2021$9.76M+25.3%
Q3 FY2021Sep 30, 2021$9.90M+59.2%
Q2 FY2021Jun 30, 2021$9.82M+102.8%
Q1 FY2021Mar 31, 2021$9.71M+76.6%
Q4 FY2020Dec 31, 2020$7.79M+7387.5%
Q3 FY2020Sep 30, 2020$6.22M+141.7%
Q2 FY2020Jun 30, 2020$4.84M-54.8%
Q1 FY2020Mar 31, 2020$5.50M-69.4%
Q1 FY2019Mar 31, 2019$104.00K-99.0%
Q4 FY2018Dec 31, 2018$2.57M-77.7%
Q3 FY2018Sep 30, 2018$10.71M+26.7%
Q2 FY2018Jun 30, 2018$18.00M+71.8%
Q1 FY2018Mar 31, 2018$10.51M+81.9%
Q4 FY2017Dec 31, 2017$11.56M+42.1%
Q3 FY2017Sep 30, 2017$8.46M+37.9%
Q2 FY2017Jun 30, 2017$10.48M–
Q1 FY2017Mar 31, 2017$5.78M–
Q4 FY2016Dec 31, 2016$8.13M–
Q3 FY2016Sep 30, 2016$6.13M–

More Neurogene figures

See a number that looks wrong?